Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Merck KGaA. (3/2/20). "Press Release: Erbitux Approved for First-Line Use in China in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) [Not intended for UK-based media]". Darmstadt.

Region Region China
Organisations Organisation Merck KGaA
  Group Merck (DE) (Group)
  Organisation 2 National Medical Products Administration of China (NMPA, formerly CFDA)
  Group China (govt)
Products Product Erbitux®
  Product 2 fluorouracil (INN)
     


   
Record changed: 2020-03-11

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top